Bicara Therapeutics

1. Ficerafusp alfa Ph1 interim2H 2026Ficerafusp alfa Ph1 interim, 2H 2026, notable
2. Ficerafusp alfa trial start3Q 2026Ficerafusp alfa trial start, 3Q 2026, routine
3. FORTIFI-FLEX trial start3Q 2026FORTIFI-FLEX trial start, 3Q 2026, routine
4. Ficerafusp alfa enrollment done4Q 2026Ficerafusp alfa enrollment done, 4Q 2026, notable
5. Ficerafusp alfa interimMid-2027Ficerafusp alfa interim, Mid-2027, major
6. '968 Patent PTAB Review FDAJul 14, 2027'968 Patent PTAB Review FDA, Jul 14, 2027, routine
7. Ficerafusp alfa FDA approval2028Ficerafusp alfa FDA approval, 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.